Immunovant, INC DEF 14A proxy statements

Immunovant, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on September 2, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.

Immunovant, Inc. has filed definitive additional materials related to its proxy statement with the U.S. Securities and Exchange Commission.

Immunovant, Inc. has released its definitive proxy statement for the 2025 Annual Meeting of Stockholders, outlining proposals for director elections, auditor ratification, and an advisory vote on executive compensation, while disclosing increased net losses and recent leadership changes.

Immunovant has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Immunovant will hold its 2024 Annual Meeting of Stockholders virtually on August 12, 2024, to vote on the election of directors, ratification of the independent auditor, and executive compensation.